Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Mirum Pharmaceuticals Shares Surge 16% in 8 Days Since Positive Zilurgisertib Results in FOP

Mirum Pharmaceuticals Reports Positive Zilurgisertib Results in Pediatric FOP Study

+16.45% in 8 days $83.27 when we broke this story → $96.97 at 8:38 AM ET, 5 Nov 2026

Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating zilurgisertib in children aged 6 to 11 with fibrodysplasia ossificans progressiva. The trial met its efficacy goals, demonstrating a significant reduction in bone lesion volume and improved mobility compared to placebo. These findings support a planned regulatory expansion for Atebrioz in early 2027.

Thermometer, medications, tablets, medicine. Stock photo illustrating Mirum Pharmaceuticals' other story.
Mirum Pharmaceuticals, Inc. · Healthcare · Photo: stevepb / Pixabay

Key highlights

  • Mean total heterotopic ossification lesion volume decreased by 8.09 cm³ in the zilurgisertib arm versus a 9.14 cm³ increase for placebo
  • Zero patients treated with zilurgisertib developed new heterotopic ossification lesions during the 24-week double-blind period
  • Clinician-assessed joint mobility scores improved by a mean of 0.80 points in the treatment group compared to 0.09 for placebo
  • No safety signals regarding growth plate closure were identified in the pediatric cohort during the clinical evaluation
  • The company plans to submit a supplemental New Drug Application for the 6 to 11 age group in the first half of 2027

The PROGRESS Cohort 2 Findings

The PROGRESS study utilized a randomized, double-blind design where 25 pediatric patients were assigned either 75 mg of daily oral zilurgisertib or a placebo. Over the 24-week period, the treatment group demonstrated a mean total heterotopic ossification lesion volume reduction of 8.09 cubic centimeters, contrasted against a 9.14 cubic centimeter increase in the placebo arm. This delta resulted in a nominal p-value of 0.003, calculated via a Wilcoxon rank-sum test. Clinicians also observed enhanced physical function through the Cumulative Analogue Joint Involvement Scale, noting that treated patients avoided the typical annual mobility decline seen in untreated FOP cases.

Clinical Safety and Regulatory Strategy

From a safety perspective, zilurgisertib was generally well tolerated among the pediatric subjects, with no new safety signals identified compared to previous adult data. Significantly, no patients in the treatment group experienced growth plate closure, a critical factor for drugs administered to growing children. Most adverse events were categorized as mild or moderate in severity, and no participants discontinued the treatment during the double-blind phase. Based on these findings, the company expects to file a supplemental New Drug Application in the first half of 2027 to expand the current label to include patients between 6 and 12 years of age.

Expanding Rare Disease Portfolio

  • Atebrioz received its initial FDA approval for patients aged 12 and older in September 2026
  • Primary endpoints were recently met in the Phase 3 EXPAND study of LIVMARLI for cholestatic liver diseases
  • Topline data for the Phase 3 AZURE-4 study in chronic hepatitis delta virus is expected in the fourth quarter of 2026
  • Regulatory submissions for LIVMARLI and Atebrioz pediatric indications are both targeted for the first half of 2027

Financial Trajectory and Guidance

Mirum recently updated its financial outlook, raising its fiscal year 2026 global net product sales guidance to a range of $680 million to $700 million. This follows a second quarter that reported 176.2 million dollars in revenue and a strong balance sheet supported by the issuance of 690 million dollars in convertible senior notes earlier in the year. The stock currently trades with a market capitalization of approximately 5.41 billion dollars and an RSI of 45.6, reflecting a period of consolidation after a quarterly price decline of over 27 percent. Management's ability to maintain revenue growth while advancing multiple Phase 3 programs remains a key focal point.

Mirum Pharmaceuticals, Inc. share price · last month
Line chart of Mirum Pharmaceuticals, Inc.'s share price over the last month, from $82.24 on 19 Oct → $91.58 on 16 Nov; our story on 26 Oct at $83.27.

Up 10.0% since our story on 26 Oct: $83.27 when we broke it → $91.58 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$82.24
20 Oct$85.07
21 Oct$83.44
22 Oct$83.10
23 Oct$80.39
26 Oct$83.27
27 Oct$85.56
28 Oct$85.81
29 Oct$86.39
30 Oct$85.00
2 Nov$85.74
3 Nov$87.03
4 Nov$96.97
5 Nov$93.54
6 Nov$93.72
9 Nov$93.18
10 Nov$94.42
11 Nov$94.61
12 Nov$93.33
13 Nov$93.99
16 Nov$91.58
Earlier announcements by Mirum Pharmaceuticals, Inc.
DateAnnouncementAmount
12 Oct 2026Primary endpoint met in Phase 3 EXPAND study of LIVMARLI (maralixibat) in ultra-rare cholestatic liver diseasesSource: ir.mirumpharma.com–
28 Sep 2026Primary endpoint met in Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virusSource: ir.mirumpharma.com–
25 Sep 2026U.S. FDA approval received for Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressivaSource: investor.incyte.com–
05 Aug 2026Second-quarter 2026 financial results reported and full-year net product sales guidance raisedSource: SEC filing–
15 May 2026Issuance of 0.00% convertible senior notes due 2032 closed, including full exercise of optionSource: SEC filing$690.0 Million
Mirum Pharmaceuticals, Inc. · financial snapshot
Share price$83.27
Market cap$5.4B
Revenue (annual)$521M
1-month price change-6.82%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Mirum Pharmaceuticals, Inc. announcing positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ in pediatric patients.

Read the filing ↗
All Mirum Pharmaceuticals, Inc. filings and newsView all →

Track Mirum Pharmaceuticals, Inc. live

Get the next Mirum Pharmaceuticals, Inc. SEC filing seconds after it lands.

More from Mirum Pharmaceuticals, Inc.

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.